Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer-Reference-Cited by-同舟云学术

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

Published:2022-05-24 Issue:13 Volume:11 Page:2550-2560
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Doki Yuichiro¹,Ueno Makoto²^ORCID,Hsu Chih‐Hung³,Oh Do‐Youn⁴,Park Keunchil⁵^ORCID,Yamamoto Noboru⁶,Ioka Tatsuya⁷,Hara Hiroki⁸,Hayama Manabu⁹,Nii Masahiro⁹,Komuro Keiko⁹,Sugimoto Mariko⁹,Tahara Makoto¹⁰

Affiliation:

1. Osaka University Hospital Osaka Japan

2. Kanagawa Cancer Center Yokohama Japan

3. National Taiwan University Hospital and National Taiwan University Cancer Center Taipei City Taiwan

4. Department of Internal Medicine Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine Seoul Republic of Korea

5. Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea

6. National Cancer Center Hospital Tokyo Japan

7. Osaka International Cancer Institute Osaka Japan

8. Saitama Cancer Center Saitama Japan

9. AstraZeneca Osaka Japan

10. National Cancer Center Hospital East Kashiwa Japan

Funder

AstraZeneca Pharma Poland

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology